

23. A vaccine composition as claimed in claim 20 wherein the ratio of QS21:3D-MPL is from 1:1 to 1:2.5.

24. A process for making a vaccine composition according to claim 19 comprising admixing QS21 and 3D-MPL with the HIV ~~or FIV~~ antigen.

25. A method for stimulating a cytotoxic T cell response in an animal comprising introducing into said animal a cytotoxic T cell response stimulating amount of the composition of claim 19.

26. A method for stimulating a  $\gamma$ -interferon response in an animal comprising introducing into said animal a  $\gamma$ -interferon response stimulating amount of the composition of claim 19.

27. A vaccine composition as claimed in claim 19 wherein the QS21 and the 3D-MPL synergistically enhance the immune response in an animal to the HIV or FIV antigen.

28. A method of enhancing the immune response in an animal to an Human Immunodeficiency Virus (HIV) <sup>antigen</sup> ~~or Feline Immunodeficiency Virus (FIV) antigen~~ which comprises administering to the animal: (a) the HIV ~~or FIV~~ antigen, (b) QS21, and (c) 3D-MPL.

29. The method of claim 28 in which the animal is a human.

30. The method of claim 28 wherein the QS21 and the 3D-MPL are administered at a ratio of QS21:3D-MPL of from 1:10 to 10:1.

31. The method of claim 28 wherein the ratio of QS21:3D-MPL is from 1:1 to 1:2.5.

32. The method of claim 28 wherein the QS21 and 3D-MPL synergistically enhance the immune response.--